Middle East & Africa Pulmonary Arterial Hypertension Market Size & Outlook
Middle East & Africa pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
MEA pulmonary arterial hypertension market highlights
- The MEA pulmonary arterial hypertension market generated a revenue of USD 507.0 million in 2023.
- The market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 507.0 million |
| Market revenue in 2030 | USD 772.4 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, MEA region accounted for 6.9% of the global pulmonary arterial hypertension market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,501.9 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.46% in 2023. Horizon Databook has segmented the Middle East & Africa pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The Middle East and African countries are also expected to have a surge during the forecast period. Middle East and Africa together accounted for a market share of around 4.0% in 2015. The regional disease burden, increasing privatization, expanding health insurance penetration, and a desire to attract skilled healthcare providers have presented a profitable scenario for these devices in the Middle Eastern countries.
Countries such as Saudi Arabia, Qatar, United Arab Emirates, Kuwait, & Oman are prospering economies and advancements in the healthcare system are expected to increase the demand for PAH agents in this region.
On the contrary, some countries in the African region lack adequate healthcare infrastructure, to address which the countries are taking initiatives in coordinating with the WHO or other independent organizations. This is expected to help this market to further develop.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA pulmonary arterial hypertension market size, by country, 2018-2030 (US$M)
Middle East & Africa Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
